Both companies have upped their offers for Metsera amid a bidding war, but Novo Nordisk comes armed with an extra $1.9bn.
Pedersen, Maggie Fick and Bhanvi Satija COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk trimmed its full-year profit and ...
COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk lowered its full-year profit and sales forecasts again on Wednesday, in an ...
Stocks fell on Wall Street Tuesday, pulled down by losses in the same big tech companies that have been the main drivers of ...
Viking Therapeutics. Naturally, such activity raises the question as to who's next? And who might be next in line for a bid ...
Another quarterly earnings announcement from Novo Nordisk and another downgrade to earnings guidance from the Danish ...
Axios on MSN
Novo and Pfizer make their America First case in their fight over an anti-obesity biotech
Novo Nordisk and Pfizer's multibillion-dollar fight over who gets to buy an anti-obesity biotech has morphed into a narrative ...
Novo Nordisk CEO Maziar Mike Doustdar discusses demand for the Danish firm's weight-loss drug Wegovy and diabetes medication ...
The firm says it now expects full-year operating profit to grow between 4% and 7% in 2025 Read more at The Business Times.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback